2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 275

Health Equity: Access to Rituximab for Patients Comparing Variable Access in a Single Rheumatology Clinic
Abstract Number: 1676

Health Related Quality of Life over Time in a Multi-Ethnic Cohort of Patients with Systemic Lupus Erythematosus and Correlation with Disease Activity and Organ Damage
Abstract Number: 1384

Health-Related Quality of Life in Patients with Ankylosing Spondylitis in the United States
Abstract Number: 2405

Health-Related Quality of Life, Functioning, and Mental Health of Children with Chronic Non-Infectious Uveitis
Abstract Number: 2995

Healthcare Cost of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell Arteritis
Abstract Number: 2507

Healthcare Resource Utilization in Patients with Secondary Sjögren’s Syndrome Associated with RA Compared with Patients with RA in an Insured Population
Abstract Number: 496

Heart Failure Risk Among Patients with Rheumatoid Arthritis: Association with Anti-Rheumatic Drugs
Abstract Number: 2943

Helping a Non-Urban Community Walk with Ease: A Feasibility Pilot Study of an Arthritis Activity Intervention
Abstract Number: 2640

Hematologic Activity in Systemic Lupus Erythematosus: Is Splenectomy Our Best Choice?
Abstract Number: 1417

Hemophagocytic Lymphohistiocytosis (HLH) Mimickers: CXCL9 As a Potential Biomarker Distinguishing HLH from Other Hyperferritinemic Syndromes
Abstract Number: 2161

Hemophagocytic Syndrome in Adults and Association with Rheumatologic Diagnoses: US National Inpatient Trend over Nine Years
Abstract Number: 1995

Heparan Sulfates from Human Osteoarthritic Cartilage Display Increased Sulfation Pattern, Decrease the Protein Binding Capacity to FGF-2 and Increase the Binding to VEGF and Induce Changes of Human Mesenchymal Stem Cell Behavior
Abstract Number: 736

Herpes Zoster and Disseminated Zoster in Systemic Lupus Erythematosus and Lupus Nephritis: Incidence Rates in Real-World Claims Data
Abstract Number: 2767

Herpes Zoster As a Risk Factor for Polymyalgia Rheumatica: A Population-Based Study
Abstract Number: 2451

Herpes Zoster in Rheumatoid Arthritis. Prospective Single Center Study of 390 RA Patients for 5 YEARS

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].